Skip to main content
CBIO
NASDAQ Life Sciences

Crescent Biopharma Q3: $289.4M Cash, $37.7M Quarterly Loss, CR-002 Trial Underway

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$14.37
Mkt Cap
$533.758M
52W Low
$8.72
52W High
$27.41
52W Position info
65% above low
Off High info
48% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CBIO sits 65% above its 52-week low of $8.72.

Summary

Crescent ended September with $289.4M in cash after raising $133.4M net in July, against a $37.7M quarterly loss and $71.6M of nine-month R&D spend. The CR-002 APOLLO trial started in Q4 2026, with first data expected in the second half of 2027.


Key Events · Earnings and Guidance · CBIO

  • Q3 Loss Widens on Clinical Spend

    Net loss was $37.7M for Q3 and $85.8M for the nine months, with R&D up to $71.6M from $43.1M a year earlier on the ASCEND and APOLLO trial build-out.

  • Cash of $289.4M After July Raise

    Cash and equivalents reached $289.4M at September 30, 2026, including $133.4M net from the July 2026 offering and $11.1M net from ATM sales; management says this funds operations for at least twelve months.

  • ATM Leaves $188.5M Overhang

    545,524 shares were sold under the $200.0M ATM program for $11.1M net, leaving $188.5M available to sell into the market.

  • CR-002 Trial Started, Data 2H 2027

    The FDA allowed the CR-002 IND in October 2026 and the global Phase 1/2 APOLLO trial began in Q4 2026, with initial data expected in the second half of 2027.


Analysis · CBIO · Life Sciences

Crescent burned $55.3M of operating cash in the first nine months while spending $71.6M on R&D. The $289.4M cash balance — boosted by $133.4M net from the July offering and $11.1M from the ATM — keeps the company funded for at least twelve months. That runway matters because the value hinges on clinical readouts: CR-001 ASCEND monotherapy data in Q1 2027, CR-003 proof-of-concept in Q1 2027, and CR-002 APOLLO initial data in the second half of 2027. The $188.5M still available under the ATM is a standing dilution overhang on top of the 38.2M shares already outstanding.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CBIO was trading at $14.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $533.8M. The 52-week trading range was $8.72 to $27.41. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CBIO - Latest Insights

CBIO
Nov 12, 2026, 4:15 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $14.37
Real-time Price: $14.15 info
Change: -$0.220 (-2%) info
Market Cap: $525.587M info
CBIO
Oct 15, 2026, 4:26 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $12.47
Real-time Price: $14.15 info
Change: +$1.68 (+13%) info
Market Cap: $525.587M info
CBIO
Oct 05, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.91
Real-time Price: $14.15 info
Change: -$0.760 (-5%) info
Market Cap: $525.587M info
CBIO
Jul 30, 2026, 9:25 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.77
Real-time Price: $14.15 info
Change: -$0.620 (-4%) info
Market Cap: $525.587M info
CBIO
Jul 30, 2026, 7:36 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.77
Real-time Price: $14.15 info
Change: -$0.620 (-4%) info
Market Cap: $525.587M info